Literature DB >> 23136628

The Prostate Cancer Detection Rate on the Second Prostate Biopsy according to Prostate-Specific Antigen Trend.

Hyung-Sang Kim1, Chang-Yong Lee, Dong-Hun Lim, Chul-Sung Kim, Seung Baik.   

Abstract

PURPOSE: To identify the prostate cancer detection rate on the patients who had second prostate biopsy out of the patients who were reported negative in their first biopsy.
MATERIALS AND METHODS: From July 2006 to February 2012, prostate biopsy was performed on 843 patients with over 4 ng/ml and on 618 biopsy negative patients PSA was performed from between 6 months and 9 months after biopsy. On 164 patients, second biopsy was performed, and 42 patients were selected. If there was less than 10% change between PSA before the prostate biopsy and PSA measured during 6 to 9 months after the first biopsy it was considered as no change. If above 10% increase, it was considered increase and if above 10% decrease it was considered as decrease.
RESULTS: The cancer detection rate in PSA increase group was 20%, the detection rate in no change in PSA level but still over the normal range group 8.3%, and that in the PSA decrease group was 0%. When comparing prostate cancer group and non-cancer group, it is more probable to have prostate cancer when they are older, prostate volume is smaller and PSA density is higher.
CONCLUSIONS: The second biopsy is strongly recommended when PSA level shows no change or increase, age is older, prostate volume is smaller or PSA density is higher.

Entities:  

Keywords:  Biopsy; Prostate; Prostate-specific antigen; Prostatic neoplasms

Year:  2012        PMID: 23136628      PMCID: PMC3490088          DOI: 10.4111/kju.2012.53.10.686

Source DB:  PubMed          Journal:  Korean J Urol        ISSN: 2005-6737


  22 in total

1.  Necessity of repeat biopsies in men for suspected prostate cancer.

Authors:  M Noguchi; J Yahara; H Koga; O Nakashima; S Noda
Journal:  Int J Urol       Date:  1999-01       Impact factor: 3.369

2.  Determination of prostate volume with transrectal US for cancer screening. Part II. Accuracy of in vitro and in vivo techniques.

Authors:  P J Littrup; C R Williams; T K Egglin; R A Kane
Journal:  Radiology       Date:  1991-04       Impact factor: 11.105

3.  Complication rates of ultrasound-guided prostate biopsy: a nation-wide survey in Japan.

Authors:  Yoshiyuki Kakehi; Seiji Naito
Journal:  Int J Urol       Date:  2008-04       Impact factor: 3.369

4.  Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients.

Authors:  T A Stamey; J N Kabalin; J E McNeal; I M Johnstone; F Freiha; E A Redwine; N Yang
Journal:  J Urol       Date:  1989-05       Impact factor: 7.450

5.  Elevated serum prostate specific antigen levels in conjunction with an initial prostatic biopsy negative for carcinoma: who should undergo a repeat biopsy?

Authors:  G C Durkan; D R Greene
Journal:  BJU Int       Date:  1999-01       Impact factor: 5.588

6.  Serendipity in detecting disease in low prostate-specific antigen ranges.

Authors:  A N Vis; R Kranse; M Roobol; Th H van der Kwast; F H Schröder
Journal:  BJU Int       Date:  2002-03       Impact factor: 5.588

7.  Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges.

Authors:  J E Oesterling; S J Jacobsen; C G Chute; H A Guess; C J Girman; L A Panser; M M Lieber
Journal:  JAMA       Date:  1993-08-18       Impact factor: 56.272

8.  Prospective evaluation of prostate-specific antigen density and systematic biopsies for early detection of prostatic carcinoma.

Authors:  M Bazinet; A W Meshref; C Trudel; S Aronson; F Péloquin; M Nachabe; L R Bégin; M M Elhilali
Journal:  Urology       Date:  1994-01       Impact factor: 2.649

9.  Relationship between initial prostate specific antigen level and subsequent prostate cancer detection in a longitudinal screening study.

Authors:  Jo Ann V Antenor; Misop Han; Kimberly A Roehl; Robert B Nadler; William J Catalona
Journal:  J Urol       Date:  2004-07       Impact factor: 7.450

10.  Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease.

Authors:  H B Carter; J D Pearson; E J Metter; L J Brant; D W Chan; R Andres; J L Fozard; P C Walsh
Journal:  JAMA       Date:  1992 Apr 22-29       Impact factor: 56.272

View more
  2 in total

Review 1.  The safety of testosterone supplementation therapy in prostate cancer.

Authors:  James M Dupree; Gavin M Langille; Mohit Khera; Larry I Lipshultz
Journal:  Nat Rev Urol       Date:  2014-07-29       Impact factor: 14.432

2.  Prostate cancer detection rate in patients with fluctuating prostate-specific antigen levels on the repeat prostate biopsy.

Authors:  Yong Hyun Park; Jung Keun Lee; Jin-Woo Jung; Byung Ki Lee; Sangchul Lee; Seong Jin Jeong; Sung Kyu Hong; Seok-Soo Byun; Sang Eun Lee
Journal:  Prostate Int       Date:  2014-03-30
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.